new england journal of medicine impact factor 2019
Rispetto allo storico Journal Impact, l'Journal Impact 2018 di New England Journal of Medicine è diminuito del 13.29 %.Il quartile del fattore di impatto di New England Journal of Medicine è Q1.Nell'editoria accademica il fattore di impatto (impact Metric o IF in inglese e generalmente anche nella normativa e nelle … At 49 months, the subcutaneous ICD was noninferior to the transvenous ICD with respect to device-related complications and inappropriate shocks.In this multicenter, randomized, open-label trial that compared myomectomy with uterine-artery embolization in women who had symptomatic uterine fibroids and wanted to avoid hysterectomy, myomectomy resulted in a better fibroid-related quality of life at 2 years than uterine-artery embolization.Nirsevimab, a monoclonal antibody with an extended half-life, is designed to protect infants from respiratory syncytial virus disease after a single intramuscular dose. The Journal Impact 2019-2020 of New England Journal of Medicine is 37.910, which is just updated in 2020. Journal Impact 2018 di New England Journal of Medicine è 37.910 (Ultimi dati nel 2019).
Many were infected with SARS-CoV-2 at least 1 to 2 weeks before syndrome onset. Articles
Tap into groundbreaking research and clinically relevant insights Compared with historical Journal Impact data, the Metric 2019 of New England Journal of Medicine dropped by 13.29%.
The primary outcome was clinical status at 15 days, assessed on a seven-level ordinal scale. The median age of the patients was 8.3 years, and 73% were previously healthy.In a randomized, double-blind trial that treated household contacts of patients with influenza with a single dose of baloxavir or placebo, participants taking baloxavir had a lower risk of influenza (1.9%) than placebo controls (13.6%). Showing 1-20 of 28142
New England Journal of Medicine Impact Factor, IF, number of article, detailed information … Two days after challenge of vaccinated animals with intranasal and intratracheal virus, viral replication was undetectable in bronchoalveolar-lavage fluid and nasal secretions.Patients with confirmed or suspected Covid-19 were randomly assigned to receive hydroxychloroquine with azithromycin, hydroxychloroquine alone, or usual care. Severe bleeding was rare but occurred more frequently in the dual antiplatelet group.The most effective timing for renal-replacement therapy in critically ill patients is unclear.
Original ArticleAug 06, 2020 A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 Boulware D.R., Pullen M.F., Bangdiwala A.S., et al. This placebo-controlled trial involving 1447 preterm infants at 164 sites in 23 countries assessed the effectiveness of nirsevimab over 150 days after the dose was administered.This randomized trial of RSV F protein nanoparticle vaccination during pregnancy did not show efficacy (according to the prespecified success criterion) against RSV-associated, medically significant lower respiratory tract infection but suggested possible benefits with respect to other RSV-related outcomes.A phase 1a–1b trial of TY014, an IgG1 anti–yellow fever virus monoclonal antibody, did not identify worrisome safety signals.
New England Journal of Medicine - Faktor Dampak 2019-20 Ramalan 50%ilmuwan berharap New England Journal of MedicineJournal Impact 2019 akan berada di kisaran 72.0 ~ 72.5.
The Journal Impact Quartile of BMJ-British Medical Journal is Q1.